What Does Wall Street Think About Krystal Biotech (KRYS)?

Core Insights - Krystal Biotech, Inc. (NASDAQ:KRYS) is recognized as a strong buy growth stock by hedge funds, with Citi raising its price target to $336 from $320 while maintaining a Buy rating [1] - The company announced preliminary unaudited financial results for fiscal Q4 and full year 2025, projecting VYJUVEK net product revenue between $106 million and $107 million for Q4 and between $388 million and $389 million for the full year [2] - As of December 31, 2025, Krystal Biotech reported cash, cash equivalents, and investments totaling approximately $955 million [2] Financial Performance - For fiscal Q4 2025, the expected net product revenue for VYJUVEK is projected to be between $106 million and $107 million [2] - The anticipated net revenue for the full year 2025 is expected to be in the range of $388 million to $389 million [2] - The preliminary unaudited results are based on initial management analysis and are subject to adjustment, with full financial results to be reported in February 2026 [3] Company Overview - Krystal Biotech, Inc. is a biotechnology company focused on developing and commercializing pharmaceutical products, including VYJUVEK, a topical gel for treating wounds in patients with dystrophic epidermolysis bullosa (DEB) [4]